BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 19395374)

  • 1. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
    Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
    Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells.
    Meazza R; Comes A; Orengo AM; Ferrini S; Accolla RS
    Eur J Immunol; 2003 May; 33(5):1183-92. PubMed ID: 12731043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer.
    Mortara L; Giuliani L; De Lerma Barbaro A; Accolla RS; Noonan DM
    Surg Oncol; 2007 Dec; 16 Suppl 1():S33-6. PubMed ID: 18035537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive expression of CIITA directs CD4 T cells to produce Th2 cytokines in the thymus.
    Patel DR; Li W; Park JS; Sofi MH; Gourley TS; Hangoc G; Kaplan MH; Chang CH
    Cell Immunol; 2005 Jan; 233(1):30-40. PubMed ID: 15876426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
    Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
    J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus.
    Rosato A; Dalla Santa S; Zoso A; Giacomelli S; Milan G; Macino B; Tosello V; Dellabona P; Lollini PL; De Giovanni C; Zanovello P
    Cancer Res; 2003 May; 63(9):2158-63. PubMed ID: 12727834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy.
    Frangione V; Mortara L; Castellani P; De Lerma Barbaro A; Accolla RS
    Int J Cancer; 2010 Oct; 127(7):1614-24. PubMed ID: 20091859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating endogenous CD49b-expressing CD4 and CD8 T effector cell subpopulations producing IL-10.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abdulsamad K; Adams SL
    Immunol Invest; 2008; 37(4):315-38. PubMed ID: 18569073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive transfer of transplantation tolerance mediated by CD4+CD25+ and CD8+CD28- regulatory T cells induced by anti-donor-specific T-cell vaccination.
    Wang J; Zhang L; Tang J; Jiang S; Wang X
    Transplant Proc; 2008 Jun; 40(5):1612-7. PubMed ID: 18589160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
    Stoppacciaro A; Forni G; Colombo MP
    Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
    Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M; Argentati K; Tibaldi A
    Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.
    Jabrane-Ferrat N; Campbell MJ; Esserman LJ; Peterlin BM
    Cancer Gene Ther; 2006 Nov; 13(11):1002-10. PubMed ID: 16841083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth.
    Martin BK; Frelinger JG; Ting JP
    J Immunol; 1999 Jun; 162(11):6663-70. PubMed ID: 10352284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.
    Cormary C; Gonzalez R; Faye JC; Favre G; Tilkin-Mariamé AF
    Cancer Gene Ther; 2004 Jul; 11(7):497-507. PubMed ID: 15153937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of hMIP-1beta gene modification on in vivo tumorigenicity and vaccine efficacy of tumor cells].
    Luo XL; Xie YA; Kuang ZP; Wu JN; Liang AM
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):97-102. PubMed ID: 18646689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New strategies of mammary cancer vaccination.
    Accolla RS; Frangione V; De Lerma Barbaro A; Mortara L
    Breast J; 2010; 16 Suppl 1():S42-4. PubMed ID: 21050309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.